{"success":true,"data":{"pressRelease":{"id":"102009","rtpr_id":"nGNX2LcWjq","ticker":"ALLO","exchange":"NASDAQ","all_tickers":["ALLO"],"title":"Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma","author":"Globe Newswire","published_at":"2026-07-29T12:30:00.136Z","article_body":"* FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis,\nHighlighting Cema-Cel’s Potential to Transform Disease Treatment in\nFirst-Line LBCL Consolidation\n* * Cema-Cel Induced Rapid and Substantial MRD Clearance of 58.3%, with a\n97.7% Median Decrease in Plasma ctDNA at Day 45, Compared With a 26.6% Median\nIncrease in the Observation Arm\n* Cema-Cel Was Well-Tolerated, With Most Patients Managed in the Outpatient\nSetting and No Hospitalizations for Treatment-Related Adverse Events\n \n* FDA Also Granted Fast Track Designation to Cema-Cel for the ALPHA3\nDevelopment Program\n* RMAT and Fast Track Status Enable Enhanced FDA Engagement and Support\nPotential Expedited Development and Review Pathways\nSOUTH SAN FRANCISCO, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Allogene\nTherapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company\npioneering allogeneic CAR T (AlloCAR T) products for cancer and autoimmune\ndisease, today announced that the U.S. Food and Drug Administration (FDA) has\ngranted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track\ndesignations to cemacabtagene ansegedleucel (cema-cel) for the treatment of\nadult patients with large B-cell lymphoma (LBCL) who, at the completion of\nfirst-line (1L) therapy, are in complete or partial response suitable for\nobservation but test positive for minimal residual disease (MRD). Together,\nthe designations enable more frequent FDA engagement and support an efficient\ndevelopment and review process.\n\nCema-cel is an investigational allogeneic CAR T product being studied in the\npivotal ALPHA3 trial as part of 1L treatment for patients with LBCL who are at\nhigh risk of relapse. The ALPHA3 trial uses Natera's CLARITY(™) MRD assay,\nwhich is powered by its phased variant MRD technology, to identify patients\nin remission but who are likely to experience disease recurrence following\ncompletion of 1L chemoimmunotherapy. Patients who test positive for MRD are\nenrolled and assigned to receive either a single dose of cema-cel or close\nobservation, the current standard of care, with outcomes compared between the\ntwo groups.\n\n“The FDA’s decision to grant both RMAT and Fast Track designations\nprovides additional validation for the strategy we defined with the ALPHA3\ntrial and strengthens our ability to work closely with the agency on an\nefficient path to advance cema-cel as a first-line consolidation therapy for\nlarge B-cell lymphoma,” said Zachary Roberts, M.D., Ph.D., President and\nChief Executive Officer of Allogene Therapeutics. “There is a shared goal\nacross the treatment community to reach patients earlier in their disease\ncourse and reduce the barriers that limit access to CAR T therapy. The interim\nALPHA3 findings, which showed rapid and substantial MRD reduction, with most\npatients treated in the outpatient setting, support cema-cel’s potential as\nan off-the-shelf therapy that can be delivered at scale in community settings\nwhere approximately 80% of first-line patients receive their care.”\n\nThe FDA granted RMAT designation for cema-cel as 1L consolidation therapy for\npatients with high-risk LBCL following full review of the interim futility\nanalysis from the ongoing ALPHA3 trial, underscoring the continued need for\nnew treatment options. At the protocol-defined data cutoff, triggered when the\n24(th) patient enrolled in the ongoing study arms completed the Day 45 MRD\nassessment, 58.3% (7/12) of patients in the cema-cel arm achieved MRD\nnegativity compared to 16.7% (2/12) in the observation arm. This represents a\n41.6% absolute difference in MRD clearance between the two arms. Published\nliterature and cross-study benchmarks suggest that MRD clearance differences\nof 25-30% may lead to clinically meaningful improvement at study completion.\n\nCema-cel was well-tolerated as of the data cutoff with no treatment-related\nserious adverse events. There were no cases of cytokine release syndrome\n(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS),\ngraft-versus-host disease (GvHD) or high-grade infections. No tocilizumab or\nsteroids were administered for toxicity prophylaxis or treatment, and no\npatients were hospitalized for treatment-related adverse events. This profile\ncompares favorably with the broader CAR T experience, where hospitalization\nfor toxicity management remains common.\n\nRegenerative Medicine Advanced Therapy (RMAT) designation is intended to\nexpedite the development and review of regenerative medicine therapies\nintended to treat, modify, or cure a serious or life-threatening disease or\nconditions when preliminary clinical evidence indicates the therapy has the\npotential to address an unmet medical need for that disease or\ncondition. Fast Track designation further supports expedited development and\nreview, including potential eligibility for rolling review and priority\nreview, if relevant criteria are met.\n\nAbout Allogene Therapeutics\nAllogene Therapeutics, with headquarters in South San Francisco, is a\nclinical-stage biotechnology company pioneering the development of allogeneic\nchimeric antigen receptor T cell (AlloCAR T) products for cancer and\nautoimmune disease. Led by cell therapy veterans applying proven CAR T\nexperience, Allogene is developing a pipeline of off-the-shelf CAR T cell\nproduct candidates with the goal of delivering readily available cell therapy\non-demand, more reliably, and at greater scale to more patients. For more\ninformation, please visit www.allogene.com, and follow Allogene\nTherapeutics on X and LinkedIn.\n\nCautionary Note on Forward-Looking Statements for Allogene \nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. The press release may,\nin some cases, use terms such as “anticipate,” “expect,”\n“believe,” “aim,” “plan,” “goal,” “intend,” “seek,”\n“estimate,” “target,” “potential,” “may,” “could,”\n“will,” “would,” “should,” “designed to,” “suggest,”\n“support,” “enable,” “possible” and similar expressions to\nidentify these forward-looking statements. Forward-looking statements include\nstatements regarding intentions, beliefs, projections, outlook, analyses or\ncurrent expectations concerning, among other things: the potential benefits\nand regulatory implications of the RMAT and Fast Track designations for\ncema-cel, including enhanced FDA engagement, an efficient or expedited\ndevelopment and review process, and potential eligibility for rolling review\nor priority review; the ongoing pivotal Phase 2 ALPHA3 trial and the potential\nfor the trial or its results to support the advancement or regulatory approval\nof cema-cel; the potential clinical benefits, safety, tolerability, durability\nand efficacy of cema-cel, including its potential to transform treatment and\nenable earlier intervention for patients with LBCL who are at high risk of\nrelapse; the interpretation and predictive value of the interim futility\nanalysis and the reported MRD clearance and plasma ctDNA results, including\nwhether the observed differences or literature-based benchmarks will translate\ninto clinically meaningful improvement or improved clinical outcomes at study\ncompletion; the ability of Natera’s CLARITY™ MRD assay to identify\npatients who are likely to experience disease recurrence following first-line\ntreatment; cema-cel’s potential as an off-the-shelf therapy that can be\ndelivered at scale in outpatient and community settings and broaden patient\naccess to CAR T therapy; comparisons of cema-cel’s safety, tolerability and\noutpatient administration profile with the broader CAR T experience; and\nAllogene’s ability to develop and deliver readily available allogeneic CAR T\nproducts on-demand, more reliably and at greater scale to more patients.\nActual results may differ materially from those indicated by these\nforward-looking statements as a result of various important factors,\nincluding, but not limited to: risks and uncertainties inherent in clinical\ndevelopment, including that interim or early data from a small number of\npatients may not be predictive of later or final results and may change as\nadditional patients are enrolled and followed; uncertainties related to MRD\nand ctDNA testing and their clinical significance, reliability and ability to\npredict clinical outcomes, including whether MRD clearance will translate into\nimprovements in event-free survival or other clinical endpoints; limitations\nof comparisons to published literature, cross-study benchmarks or other CAR T\ntherapies; the occurrence of adverse safety events; patient enrollment and\ntrial execution risks; regulatory risks and uncertainties, including that RMAT\nor Fast Track designation does not ensure expedited development or review or\nregulatory approval and that the FDA may disagree with Allogene’s clinical\nor regulatory plans, interpretation of results or proposed development pathway\nor may require additional data or trials; risks related to the development,\nregulatory approval and performance of the CLARITY™ MRD assay; manufacturing\nand CMC risks; reliance on third parties and licensors; competitive\ndevelopments; intellectual property and contractual risks; and financial\nrisks, including the need for additional capital. These and other risks and\nuncertainties are described more fully in Allogene’s filings with the SEC,\nincluding under the heading “Risk Factors” in its Annual Report on Form\n10-K for the year ended December 31, 2025, filed with the SEC on March 12,\n2026, and its Quarterly Report on Form 10-Q for the quarter ended March 31,\n2026, filed with the SEC on May 13, 2026, and other filings that Allogene may\nmake from time to time with the SEC. All forward-looking statements in this\npress release speak only as of the date of this press release, and Allogene\nundertakes no obligation to update or revise any forward-looking statements,\nwhether as a result of new information, future events or otherwise, except as\nrequired by law.\n\nAllogene’s investigational AlloCAR T oncology products utilize Cellectis\ntechnologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an\nexclusive license granted by Cellectis to Servier. Servier has granted\nAllogene exclusive rights to cema-cel in the U.S., all EU Member States and\nthe United Kingdom.\n\nAllogene Media/Investor Contact:\nChristine Cassiano\nEVP, Chief Corporate Affairs & Brand Strategy Officer\nChristine.Cassiano@allogene.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/87e8712c-0741-409f-9942-c91b31e7c5e1)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2LcWjq","title":"Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma","author":"Globe Newswire","ticker":"ALLO","created":"2026-07-29T12:30:00.136Z","tickers":["ALLO"],"exchange":"NASDAQ","article_body":"* FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis,\nHighlighting Cema-Cel’s Potential to Transform Disease Treatment in\nFirst-Line LBCL Consolidation\n* * Cema-Cel Induced Rapid and Substantial MRD Clearance of 58.3%, with a\n97.7% Median Decrease in Plasma ctDNA at Day 45, Compared With a 26.6% Median\nIncrease in the Observation Arm\n* Cema-Cel Was Well-Tolerated, With Most Patients Managed in the Outpatient\nSetting and No Hospitalizations for Treatment-Related Adverse Events\n \n* FDA Also Granted Fast Track Designation to Cema-Cel for the ALPHA3\nDevelopment Program\n* RMAT and Fast Track Status Enable Enhanced FDA Engagement and Support\nPotential Expedited Development and Review Pathways\nSOUTH SAN FRANCISCO, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Allogene\nTherapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company\npioneering allogeneic CAR T (AlloCAR T) products for cancer and autoimmune\ndisease, today announced that the U.S. Food and Drug Administration (FDA) has\ngranted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track\ndesignations to cemacabtagene ansegedleucel (cema-cel) for the treatment of\nadult patients with large B-cell lymphoma (LBCL) who, at the completion of\nfirst-line (1L) therapy, are in complete or partial response suitable for\nobservation but test positive for minimal residual disease (MRD). Together,\nthe designations enable more frequent FDA engagement and support an efficient\ndevelopment and review process.\n\nCema-cel is an investigational allogeneic CAR T product being studied in the\npivotal ALPHA3 trial as part of 1L treatment for patients with LBCL who are at\nhigh risk of relapse. The ALPHA3 trial uses Natera's CLARITY(™) MRD assay,\nwhich is powered by its phased variant MRD technology, to identify patients\nin remission but who are likely to experience disease recurrence following\ncompletion of 1L chemoimmunotherapy. Patients who test positive for MRD are\nenrolled and assigned to receive either a single dose of cema-cel or close\nobservation, the current standard of care, with outcomes compared between the\ntwo groups.\n\n“The FDA’s decision to grant both RMAT and Fast Track designations\nprovides additional validation for the strategy we defined with the ALPHA3\ntrial and strengthens our ability to work closely with the agency on an\nefficient path to advance cema-cel as a first-line consolidation therapy for\nlarge B-cell lymphoma,” said Zachary Roberts, M.D., Ph.D., President and\nChief Executive Officer of Allogene Therapeutics. “There is a shared goal\nacross the treatment community to reach patients earlier in their disease\ncourse and reduce the barriers that limit access to CAR T therapy. The interim\nALPHA3 findings, which showed rapid and substantial MRD reduction, with most\npatients treated in the outpatient setting, support cema-cel’s potential as\nan off-the-shelf therapy that can be delivered at scale in community settings\nwhere approximately 80% of first-line patients receive their care.”\n\nThe FDA granted RMAT designation for cema-cel as 1L consolidation therapy for\npatients with high-risk LBCL following full review of the interim futility\nanalysis from the ongoing ALPHA3 trial, underscoring the continued need for\nnew treatment options. At the protocol-defined data cutoff, triggered when the\n24(th) patient enrolled in the ongoing study arms completed the Day 45 MRD\nassessment, 58.3% (7/12) of patients in the cema-cel arm achieved MRD\nnegativity compared to 16.7% (2/12) in the observation arm. This represents a\n41.6% absolute difference in MRD clearance between the two arms. Published\nliterature and cross-study benchmarks suggest that MRD clearance differences\nof 25-30% may lead to clinically meaningful improvement at study completion.\n\nCema-cel was well-tolerated as of the data cutoff with no treatment-related\nserious adverse events. There were no cases of cytokine release syndrome\n(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS),\ngraft-versus-host disease (GvHD) or high-grade infections. No tocilizumab or\nsteroids were administered for toxicity prophylaxis or treatment, and no\npatients were hospitalized for treatment-related adverse events. This profile\ncompares favorably with the broader CAR T experience, where hospitalization\nfor toxicity management remains common.\n\nRegenerative Medicine Advanced Therapy (RMAT) designation is intended to\nexpedite the development and review of regenerative medicine therapies\nintended to treat, modify, or cure a serious or life-threatening disease or\nconditions when preliminary clinical evidence indicates the therapy has the\npotential to address an unmet medical need for that disease or\ncondition. Fast Track designation further supports expedited development and\nreview, including potential eligibility for rolling review and priority\nreview, if relevant criteria are met.\n\nAbout Allogene Therapeutics\nAllogene Therapeutics, with headquarters in South San Francisco, is a\nclinical-stage biotechnology company pioneering the development of allogeneic\nchimeric antigen receptor T cell (AlloCAR T) products for cancer and\nautoimmune disease. Led by cell therapy veterans applying proven CAR T\nexperience, Allogene is developing a pipeline of off-the-shelf CAR T cell\nproduct candidates with the goal of delivering readily available cell therapy\non-demand, more reliably, and at greater scale to more patients. For more\ninformation, please visit www.allogene.com, and follow Allogene\nTherapeutics on X and LinkedIn.\n\nCautionary Note on Forward-Looking Statements for Allogene \nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. The press release may,\nin some cases, use terms such as “anticipate,” “expect,”\n“believe,” “aim,” “plan,” “goal,” “intend,” “seek,”\n“estimate,” “target,” “potential,” “may,” “could,”\n“will,” “would,” “should,” “designed to,” “suggest,”\n“support,” “enable,” “possible” and similar expressions to\nidentify these forward-looking statements. Forward-looking statements include\nstatements regarding intentions, beliefs, projections, outlook, analyses or\ncurrent expectations concerning, among other things: the potential benefits\nand regulatory implications of the RMAT and Fast Track designations for\ncema-cel, including enhanced FDA engagement, an efficient or expedited\ndevelopment and review process, and potential eligibility for rolling review\nor priority review; the ongoing pivotal Phase 2 ALPHA3 trial and the potential\nfor the trial or its results to support the advancement or regulatory approval\nof cema-cel; the potential clinical benefits, safety, tolerability, durability\nand efficacy of cema-cel, including its potential to transform treatment and\nenable earlier intervention for patients with LBCL who are at high risk of\nrelapse; the interpretation and predictive value of the interim futility\nanalysis and the reported MRD clearance and plasma ctDNA results, including\nwhether the observed differences or literature-based benchmarks will translate\ninto clinically meaningful improvement or improved clinical outcomes at study\ncompletion; the ability of Natera’s CLARITY™ MRD assay to identify\npatients who are likely to experience disease recurrence following first-line\ntreatment; cema-cel’s potential as an off-the-shelf therapy that can be\ndelivered at scale in outpatient and community settings and broaden patient\naccess to CAR T therapy; comparisons of cema-cel’s safety, tolerability and\noutpatient administration profile with the broader CAR T experience; and\nAllogene’s ability to develop and deliver readily available allogeneic CAR T\nproducts on-demand, more reliably and at greater scale to more patients.\nActual results may differ materially from those indicated by these\nforward-looking statements as a result of various important factors,\nincluding, but not limited to: risks and uncertainties inherent in clinical\ndevelopment, including that interim or early data from a small number of\npatients may not be predictive of later or final results and may change as\nadditional patients are enrolled and followed; uncertainties related to MRD\nand ctDNA testing and their clinical significance, reliability and ability to\npredict clinical outcomes, including whether MRD clearance will translate into\nimprovements in event-free survival or other clinical endpoints; limitations\nof comparisons to published literature, cross-study benchmarks or other CAR T\ntherapies; the occurrence of adverse safety events; patient enrollment and\ntrial execution risks; regulatory risks and uncertainties, including that RMAT\nor Fast Track designation does not ensure expedited development or review or\nregulatory approval and that the FDA may disagree with Allogene’s clinical\nor regulatory plans, interpretation of results or proposed development pathway\nor may require additional data or trials; risks related to the development,\nregulatory approval and performance of the CLARITY™ MRD assay; manufacturing\nand CMC risks; reliance on third parties and licensors; competitive\ndevelopments; intellectual property and contractual risks; and financial\nrisks, including the need for additional capital. These and other risks and\nuncertainties are described more fully in Allogene’s filings with the SEC,\nincluding under the heading “Risk Factors” in its Annual Report on Form\n10-K for the year ended December 31, 2025, filed with the SEC on March 12,\n2026, and its Quarterly Report on Form 10-Q for the quarter ended March 31,\n2026, filed with the SEC on May 13, 2026, and other filings that Allogene may\nmake from time to time with the SEC. All forward-looking statements in this\npress release speak only as of the date of this press release, and Allogene\nundertakes no obligation to update or revise any forward-looking statements,\nwhether as a result of new information, future events or otherwise, except as\nrequired by law.\n\nAllogene’s investigational AlloCAR T oncology products utilize Cellectis\ntechnologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an\nexclusive license granted by Cellectis to Servier. Servier has granted\nAllogene exclusive rights to cema-cel in the U.S., all EU Member States and\nthe United Kingdom.\n\nAllogene Media/Investor Contact:\nChristine Cassiano\nEVP, Chief Corporate Affairs & Brand Strategy Officer\nChristine.Cassiano@allogene.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/87e8712c-0741-409f-9942-c91b31e7c5e1)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-29T12:30:00.17926498Z","server_sent_at_ms":1785328200179},"received_at":"2026-07-29T12:30:00.315Z","source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335229/0/en/allogene-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-cemacabtagene-ansegedleucel-cema-cel-as-first-line-consolidation-therapy-for-large-b-.html"},"analysis":{"id":"91031","press_release_id":"102009","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Allogene Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to Cema-Cel for first-line consolidation therapy in large B-cell lymphoma.\n\nThe designations are supported by interim data from the pivotal ALPHA3 trial, showing Cema-Cel achieved 58.3% MRD negativity versus 16.7% in the observation arm, with a 97.7% median decrease in plasma ctDNA compared to a 26.6% increase in the control arm.\n\nSafety data was favorable, with no treatment-related serious adverse events, CRS, ICANS, or GvHD reported, and most patients were managed in the outpatient setting.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Dual RMAT and Fast Track designations for Cema-Cel accelerate the regulatory pathway following strong interim efficacy and safety data in first-line LBCL."},"keyFigures":{"drugName":"cemacabtagene ansegedleucel (cema-cel)","phaseOfTrial":"pivotal ALPHA3 trial","customDimensions":{"mrd_negativity_cema_cel":"58.3%","mrd_negativity_observation":"16.7%","absolute_difference_mrd_clearance":"41.6%","median_decrease_plasma_ctdna_cema_cel":"97.7%","median_increase_plasma_ctdna_observation":"26.6%"}},"quotedText":"The FDA’s decision to grant both RMAT and Fast Track designations provides additional validation for the strategy we defined with the ALPHA3 trial and strengthens our ability to work closely with the agency on an efficient path to advance cema-cel as a first-line consolidation therapy for large B-cell lymphoma","namedEntities":{"people":[{"name":"Zachary Roberts","role":"President and CEO"}],"products":["cemacabtagene ansegedleucel","Cema-Cel","CLARITY MRD assay","AlloCAR T"],"companies":[{"name":"Allogene Therapeutics, Inc.","ticker":"ALLO"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Natera","relationship":"assay provider"},{"name":"Cellectis","relationship":"technology licensor"},{"name":"Servier","relationship":"licensor"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Receipt of both RMAT and Fast Track designations for lead asset Cema-Cel based on positive interim futility analysis showing significant MRD clearance benefit. These designations facilitate expedited review and enhanced FDA engagement, de-risking the regulatory path."},"tickerRelevance":{"others":[],"primary":"ALLO"},"globalImportance":30,"audienceRelevance":35,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"regulatory_designation_positive","sectorWeight":"biotech"}},"event_type":"regulatory","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":4,"narrative":"Allogene Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to Cema-Cel for first-line consolidation therapy in large B-cell lymphoma.\n\nThe designations are supported by interim data from the pivotal ALPHA3 trial, showing Cema-Cel achieved 58.3% MRD negativity versus 16.7% in the observation arm, with a 97.7% median decrease in plasma ctDNA compared to a 26.6% increase in the control arm.\n\nSafety data was favorable, with no treatment-related serious adverse events, CRS, ICANS, or GvHD reported, and most patients were managed in the outpatient setting.","key_figures":{"drugName":"cemacabtagene ansegedleucel (cema-cel)","phaseOfTrial":"pivotal ALPHA3 trial","customDimensions":{"mrd_negativity_cema_cel":"58.3%","mrd_negativity_observation":"16.7%","absolute_difference_mrd_clearance":"41.6%","median_decrease_plasma_ctdna_cema_cel":"97.7%","median_increase_plasma_ctdna_observation":"26.6%"}},"named_entities":{"people":[{"name":"Zachary Roberts","role":"President and CEO"}],"products":["cemacabtagene ansegedleucel","Cema-Cel","CLARITY MRD assay","AlloCAR T"],"companies":[{"name":"Allogene Therapeutics, Inc.","ticker":"ALLO"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Natera","relationship":"assay provider"},{"name":"Cellectis","relationship":"technology licensor"},{"name":"Servier","relationship":"licensor"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-29T16:35:42.137Z","global_importance":30,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap","eventGravity":"regulatory_designation_positive","sectorWeight":"biotech"}},"durationMs":null,"modelName":"glm-4.7"}}